Amoy Diagnostics Co., Ltd. (SHE:300685)

Market Cap	8.71B -14.6%
Revenue (ttm)	1.20B +8.0%
Net Income	357.89M +40.4%
EPS	0.90 +40.6%
Shares Out	386.86M
PE Ratio	25.02
Forward PE	21.76
Dividend	0.30 (1.37%)
Ex-Dividend Date	Jun 3, 2025

Volume	9,464,300
Average Volume	7,602,712
Open	21.01
Previous Close	22.52
Day's Range	21.01 - 22.80
52-Week Range	19.27 - 26.15
Beta	0.71
RSI	68.85
Earnings Date	Apr 28, 2026

About Amoy Diagnostics

Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx comprehensive panel, a sequencing-based test capable of detecting a range of alterations; AmoyDx HRD complete panel, detects genetic aberrations across HRR genes and...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2008
• Employees: 1,144
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300685

Financial Performance

In 2025, Amoy Diagnostics's revenue was 1.20 billion, an increase of 8.00% compared to the previous year's 1.11 billion. Earnings were 357.89 million, an increase of 40.42%.